A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001300|
Recruitment Status : Completed
First Posted : December 10, 2002
Last Update Posted : March 4, 2008
Randomized study. All patients must be randomized to treatment on Arms I and II within 3 months of definitive surgery on Regimen A.
Regimen A: Surgery followed, as indicated, by Radiotherapy. Amputation; or limb-sparing resection followed by involved-field irradiation using megavoltage equipment with or without electron boost.
Arm I: 2-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation and Urothelial Protection. Doxorubicin, DOX, NSC-123127; Ifosfamide, IFF, NSC-109724; with Granulocyte Colony Stimulating Factor (Amgen), G-CSF,
NSC-614629; and Mesna, NSC-113891.
Arm II: Observation. No adjuvant chemotherapy.
|Condition or disease||Intervention/treatment||Phase|
|Sarcoma||Drug: doxorubicin Drug: ifosfamide Drug: mesna||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||150 participants|
|Official Title:||A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma|
|Study Start Date :||June 1992|
|Study Completion Date :||March 2001|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001300
|United States, Maryland|
|National Cancer Institute (NCI)|
|Bethesda, Maryland, United States, 20892|